hepatex (paziņots 2011.) tablete
ppf hasco-lek s.a. - tablete
ristempa
amgen europe b.v. - pegfilgrastim - neitropēnija - imunitātes stimulatori, - ilguma samazināšanās neutropenia un saslimstība ar pieaugušiem pacientiem drudža neutropenia ārstēti ar citotoksiskas ķīmijterapijas ļaundabīgo audzēju (izņemot myeloid hroniskas leikēmijas un myelodysplastic sindromi).
solymbic
amgen europe b.v. - adalimumab - arthritis, psoriatic; spondylitis, ankylosing; crohn disease; colitis, ulcerative; hidradenitis suppurativa; psoriasis; arthritis, rheumatoid - imūnsupresanti - lūdzu, skatiet 4. sadaļu. produkta raksturojuma kopsavilkums 1 produkta informācijas dokumentā.
actilyse 50 mg pulveris un šķīdinātājs injekciju un infūziju šķīduma pagatavošanai
boehringer ingelheim international gmbh, germany - alteplāze - pulveris un šķīdinātājs injekciju un infūziju šķīduma pagatavošanai - 50 mg ar šķīdinātāju 50 ml
septanazal 1 mg/50 mg/ml deguna aerosols, šķīdums pieaugušajiem
krka, d.d., novo mesto, slovenia - xylometazolini hydrochloridum, dexpanthenolum - deguna aerosols, šķīdums - 1 mg/50 mg/ml
flucinar n 0,25 mg/5 mg/g ziede
pharmaswiss ceska republika s.r.o., czech republic - fluocinoloni acetonidum, neomycini sulfas - ziede - 0,25 mg/5 mg/g
aktivĒtĀ ogle tablete
eiro plus, privātuzņēmums - tablete
aranesp
amgen europe b.v. - darbepoetin alfa - anemia; cancer; kidney failure, chronic - citi antianēmiskie līdzekļi - simptomātiskas anēmijas, kas saistītas ar hronisku nieru mazspēju (crf), ārstēšana pieaugušajiem un bērniem. Ārstēšana simptomātiska anēmija pieaugušo vēža pacientiem ar ne-mieloīdu ļaundabīgu audzēju, kas saņem ķīmijterapiju,.
blincyto
amgen europe b.v. - blinatumomab - prekursoru šūnu limfoblastiska leikēmija-limfoma - antineoplastiski līdzekļi - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.